A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.

Trial Details

NCT ID
NCT07714668
Phase
PHASE2
Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • SYS6041, bevacizumab
  • SYS6041, carboplatin, bevacizumab
  • paclitaxel, carboplatin, bevacizumab
  • SYS6041, enlonstobart, bevacizumab
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Fully understand this clinical trial and voluntarily sign the written informed consent form
  • Age ≥ 18 years old
  • Histologically or cytologically confirmed high-grade serous ovarian, epithelial fallopian tube carcinoma, and primary peritoneal cancer
  • Cohort A and B:subjects with platinum-sensitive disease who have received ≤2 prior lines of systemic chemotherapy and if have a BRCAm or HRD-positi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →